A recombinant slow-release PACAP-derived peptide alleviates diabetes by promoting both insulin secretion and actions

Biomaterials

Volumn 51, Issue , 2015, Pages 80-90

  Ma, Yi ^a   Fang, Shixiong ^a   Zhao, Shaojun ^a   Wang, Xiaoli ^a   Wang, Dongbo ^a   Ma, Min ^b   Luo, Tianjie ^a   Hong, An ^a  

^a JINAN UNIVERSITY   (China)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

Diabetes; Gene recombination; Insulin; Pituitary adenylate cyclase activating polypeptide (PACAP) derived peptide; Slow release; VPAC2 receptor

Indexed keywords

CHEMICAL ACTIVATION; CONTROLLED DRUG DELIVERY; GLUCOSE; INSULIN; MAMMALS; MEDICAL PROBLEMS; PHAGE DISPLAY; TARGETED DRUG DELIVERY;

ADENYLATE CYCLASE; DIPEPTIDYL PEPTIDASE IV; INSULINOTROPIC ACTIVITY; PHAGE DISPLAY SCREENING; SLOW RELEASE; THERAPEUTIC APPLICATION; THERAPEUTIC PEPTIDES; VPAC2 RECEPTOR;

PEPTIDES;

ALBUMIN; AMINO ACID; BLOOD CLOTTING FACTOR 10A; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLUCOSE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; LIPID; PROTEINASE; RECOMBINANT HORMONE; RECOMBINANT SLOW RELEASE PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE DERIVED PEPTIDE; SERUM ALBUMIN; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION; GLUCOSE BLOOD LEVEL; INSULIN; RECOMBINANT PROTEIN; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; DIABETES MELLITUS; DRUG HALF LIFE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IN VITRO STUDY; INSULIN RELEASE; INSULIN SENSITIVITY; MOUSE; NEW ZEALAND RABBIT; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; AMINO ACID SEQUENCE; ANIMAL; BLOOD; CHEMISTRY; CHO CELL LINE; CRICETULUS; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, EXPERIMENTAL; ESCHERICHIA COLI; HALF LIFE TIME; HAMSTER; HUMAN; INSULIN RESISTANCE; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; RABBIT; SECRETION (PROCESS); SURFACE PLASMON RESONANCE;

ANIMALIA; MUS; ORYCTOLAGUS CUNICULUS;

AMINO ACID SEQUENCE; ANIMALS; BLOOD GLUCOSE; CHO CELLS; CRICETINAE; CRICETULUS; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, EXPERIMENTAL; ESCHERICHIA COLI; HALF-LIFE; HUMANS; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; LIPIDS; MICE; MOLECULAR SEQUENCE DATA; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RABBITS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECOMBINANT PROTEINS; SERUM ALBUMIN; SURFACE PLASMON RESONANCE;

EID: 84924862393     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.01.064     Document Type: Article

References (42)

1. Laburthe M., Couvineau A., Marie J.C. VPAC receptors for VIP and PACAP. Recept Channels 2002, 8:137-153.
2. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 2000, 52:269-324.
3. Reglodi D., Lubics A., Kiss P., Lengvari I., Gaszner B., Toth G., et al. Effect of PACAP in 6-OHDA-induced injury of the substantia nigra in intact young and ovariectomized female rats. Neuropeptides 2006, 40:265-274.
4. Ma Y., Ma M., Dai Y., Hong A. Expression, identification and biological effects of a novel VPAC2-specific agonist with high stability and bioactivity. Acta Biochim Biophys Sin Shanghai 2010, 42:21-29.
5. Gomariz R.P., Juarranz Y., Abad C., Arranz A., Leceta J., Martinez C. VIP-PACAP system in immunity - new insights for multitarget therapy. Ann N Y Acad Sci 2006, 1070:51-74.
6. Arimura A., Li M., Batuman V. Treatment of renal failure associated with multiple myeloma and other diseases by PACAP38. Ann N Y Acad Sci 2006, 1070:1-4.
7. Gray S.L., Cummings K.J., Jirik F.R., Sherwood N.M. Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. Mol Endocrinol 2001, 15:1739-1747.
8. Nakata M., Kohno D., Shintani N., Nemoto Y., Hashimoto H., Baba A., et al. PACAP deficient mice display reduced carbohydrate intake and PACAP activates NPY-containing neurons in the rat hypothalamic arcuate nucleus. Neurosci Lett 2004, 370:252-256.
9. Tomimoto S., Qjika T., Shintani N., Hashimoto H., Hamagami K., Ikeda K., et al. Markedly reduced white adipose tissue and increased insulin sensitivity in Adcyap1-deficient mice. JPharmacol Sci 2008, 107:41-48.
10. Green B.D., Irwin N., Flatt P.R. Direct and indirect effects of obestatin peptides on food intake and the regulation of glucose homeostasis and insulin secretion in mice. Peptides 2007, 28:981-987.
11. Yada T., Sakurada M., Filipsson K., Kikuchi M., Ahren B. Intraperitoneal PACAP administration decreases blood glucose in GK rats, and in normal and high fat diet mice. Ann N Y Acad Sci 2000, 921:259-263.
12. Asnicar M.A., Koster A., Heiman M.L., Tinsley F., Smith D.P., Galbreath E., et al. Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate. Endocrinology 2002, 143:3994-4006.
13. Tsutsumi M., Claus T.H., Liang Y., Li Y.X., Yang L., Zhu J., et al. Apotent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal - a potential therapy for type 2 diabetes. Diabetes 2002, 51:1453-1460.
14. Yamamoto K., Hashimoto H., Tomimoto S., Shintani N., Miyazaki J., Tashiro F., et al. Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. Diabetes 2003, 52:1155-1162.
15. Gourlet P., De Neef P., Cnudde J., Waelbroeck M., Robberecht P. Invitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides 1997, 18:1555-1560.
16. Xia M., Sreedharan S.P., Bolin D.R., Gaufo G.O., Goetzl E.J. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. JPharmacol Exp Ther 1997, 281:629-633.
17. Yung S.L., Dela Cruz F., Hamren S., Zhu J., Tsutsumi M., Bloom J.W., et al. Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide. JBiol Chem 2003, 278:10273-10281.
18. Hamelink C., Tjurmina O., Damadzic R., Young W.S., Weihe E., Lee H.W., et al. Pituitary adenylate cyclase-activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucohomeostasis. Proc Natl Acad Sci U S A 2002, 99:461-466.
19. McGregor D.P. Discovering and improving novel peptide therapeutics. Curr Opin Pharmacol 2008, 8:616-619.
20. Pan C.Q., Li F., Tom I., Wang W., Dumas M., Froland W., et al. Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity invivo. JPharmacol Exp Ther 2007, 320:900-906.
21. Malik D.K., Baboota S., Ahuja A., Hasan S., Ali J. Recent advances in protein and peptide drug delivery systems. Curr Drug Deliv 2007, 4:141-151.
22. Pawar R., Ben-Ari A., Domb A.J. Protein and peptide parental controlled delivery. Expert Opin Biol Ther 2004, 4:1203-1212.
23. Dennis M.S., Zhang M., Meng Y.G., Kadkhodayan M., Kirchhofer D., Combs D., et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. JBiol Chem 2002, 277:35035-35043.
24. Conti R., Mannucci E., Pessotto P., Tassoni E., Carminati P., Giannessi F., et al. Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by Teglicar reduces gluconeogenesis and improves glucose homeostasis. Diabetes 2011, 60:644-651.
25. Moller D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001, 414:821-827.
26. Walsh G. Biopharmaceutical benchmarks 2010. Nat Biotechnol 2010, 28:917-924.
27. Marx V. Watching peptide drugs grow up. Chem Eng News 2005, 83:17-24.
28. Sato A.K., Viswanathan M., Kent R.B., Wood C.R. Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 2006, 17:638-642.
29. Dejager S., Schweizer A. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment. Hosp Pract 1995, 2012(40):7-21.
30. Vilsboll T. The effects of glucagon-like peptide-1 on the beta cell. Diabetes Obes Metab 2009, 11:11-18.
31. Aroda V.R., Henry R.R., Han J., Huang W., DeYoung M.B., Darsow T., et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012, 34:1247-1258.
32. Arulmozhi D.K., Portha B. GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci 2006, 28:96-108.
33. Pozo D. VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools. Trends Mol Med 2003, 9:211-217.
34. Picha K.M., Cunningham M.R., Drucker D.J., Mathur A., Ort T., Scully M., et al. Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis. Diabetes 2008, 57:1926-1934.
35. Stork R., Mueller D., Kontermann R.E. Anovel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel 2007, 20:569-576.
36. Mueller D., Karle A., Meissburger B., Hoefig I., Stork R., Kontermann R.E. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. JBiol Chem 2007, 282:12650-12660.
37. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005, 23:1126-1136.
38. Licari L.G., Kovacic J.P. Thrombin physiology and pathophysiology. JVet Emerg Crit Care San Ant 2009, 19:11-22.
39. Borensztajn K., Peppelenbosch M.P., Spek C.A., Factor Xa at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med 2008, 14:429-440.
40. Aoki I., Shimoyama K., Aoki N., Homori M., Yanagisawa A., Nakahara K., et al. Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. JAm Coll Cardiol 1996, 27:560-566.
41. Cohen Z., Gonzales R.F., Davis-Gorman G.F., Copeland J.G., McDonagh P.F. Thrombin activity and platelet microparticle formation are increased in type 2 diabetic platelets: a potential correlation with caspase activation. Thromb Res 2002, 107:217-221.
42. Ludwig S., Dharmalingam S., Erickson-Nesmith S., Ren S., Zhu F.Q., Ma G.P.M., et al. Impact of simvastatin on hemostatic and fibrinolytic regulators in type 2 diabetes mellitus. Diabetes Res Clin Pract 2005, 70:110-118.